readthroughSign in
CompanyNAMSNAMSWNasdaqNarrden, P7

NewAmsterdam Pharma Co N.V.

NewAmsterdam Pharma develops obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol in patients with cardiovascular disease risk.

SCHEDULE 13G/ANov 16Latest SEC filing
Oct 2Latest story